A Randomized, Placebo-Controlled Trial of Sertraline for Prophylactic Treatment of Highly Recurrent Major Depressive Disorder

American Journal of Psychiatry

Volumn 161, Issue 5, 2004, Pages 836-842

  Lépine, Jean Pierre ^a   Caillard, Vincent ^b   Bisserbe, Jean Claude ^b   Troy, Sylvie ^b   Hotton, Jean Michel ^b   Boyer, Patrice ^b  

^a HÔPITAL FERNAND WIDAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RELAPSE; REMISSION; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADULT; CLINICAL PROTOCOLS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 2442501441     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.5.836     Document Type: Article

References (22)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
2. Robins LN, Regier DA (eds): Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, Free Press, 1991
3. Wells KB, Stewart A. Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J: The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262:914-919
4. Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K: Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995:52:11-19
5. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-1442
6. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229-233
7. Kupfer DJ: Long-term treatment of depression. J Clin Psychiatry 1991; 52:28-34
8. Anderson IM, Nutt DJ, Deakin JFW: Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14:3-20
9. Coppen A, Mendlewicz J, Kielholz P: Pharmacotherapy of Depressive Disorders: A Consensus Statement. Geneva, World Health Organization, 1986
10. World Health Organization Mental Health Collaborating Centers: Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989; 17:197-198
11. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-1099
12. Kocsis JH, Friedman RA, Markowitz JC, Leon AC, Miller NL, Gniwesch L, Parides M: Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry 1996; 53:769-776
13. Stewart JW, Tricamo E, McGrath PJ, Quitkin FM: Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry 1997; 154:31-36
14. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W (Sertraline Chronic Depression Study Group): Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280:1665-1672
15. Doogan DP, Caillard V: Sertraline in the prevention of depression. Br J Psychiatry 1992; 160:217-222
16. Montgomery SA, Dufour H, Brion S, Gailledreau J, LaQueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen JN, Pierredon MA: The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry Suppl 1988; 3:69-76
17. Montgomery SA, Dunbar G: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8:189-195
18. Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F, Wade AG, Andersen M, Pedersen SF, Swart JC, Nil R: Prophylactic effect of citalopram in unipolar recurrent depression. Br J Psychiatry 2001; 178:304-310
19. Greenhouse JB, Stangl D, Kupfer DJ, Prien RF: Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry 1991; 48:313-318
20. Frank E, Prien F, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851-855
21. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
22. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222